{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T18:23:57Z","timestamp":1790792637958,"version":"4.1.0"},"reference-count":38,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2011,9,13]],"date-time":"2011-09-13T00:00:00Z","timestamp":1315872000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Mult Scler"],"published-print":{"date-parts":[[2012,4]]},"abstract":"<jats:p>Background: The incidence of disease-modifying drug (DMD) exposure during pregnancy in multiple sclerosis (MS) is unknown and limited data exists regarding the potential harm of DMD exposure during pregnancy.<\/jats:p>\n                  <jats:p>Objective: To investigate the incidence and effect of in utero DMD exposure on perinatal outcomes.<\/jats:p>\n                  <jats:p>Methods: We conducted a retrospective analysis by linking two provincial, population-based databases, the British Columbia (BC) MS database with the BC Perinatal Database Registry. Delivery (duration of the second stage of labor, assisted vaginal delivery and Cesarean section) and neonatal (birth weight, gestational age, 5-minute Apgar score and congenital anomalies) outcomes were compared between women exposed and unexposed to a DMD within 1 month prior to conception and\/or during pregnancy. Findings were reported as odds ratios (ORs) with 95% confidence intervals (CIs).<\/jats:p>\n                  <jats:p>Results: In all, 311 women with relapsing\u2013remitting MS delivered 418 singleton babies between April 1998 and March 2009. 21\/101 (21%) of births to MS women treated with DMD prior to pregnancy were exposed to a DMD. In all cases, exposure was documented as unintentional and DMD treatment was stopped within 2 months of gestation. The overall incidence of exposure was 21\/418 (5%). DMD exposure was associated with a trend towards a greater risk of assisted vaginal delivery compared to the DMD na\u00efve groups (OR = 3.0; 95% CI: 1.0\u20139.2). All other comparisons of perinatal outcomes were unremarkable.<\/jats:p>\n                  <jats:p>Conclusion: The incidence of DMD exposure was relatively low and no cases were intentional. Further studies are needed to ascertain the safety of DMD exposure during pregnancy in MS.<\/jats:p>","DOI":"10.1177\/1352458511422244","type":"journal-article","created":{"date-parts":[[2011,9,13]],"date-time":"2011-09-13T21:12:53Z","timestamp":1315948373000},"page":"460-467","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":48,"title":["Perinatal outcomes in women with multiple sclerosis exposed to disease-modifying drugs"],"prefix":"10.1177","volume":"18","author":[{"given":"E","family":"Lu","sequence":"first","affiliation":[{"name":"Faculty of Medicine, Experimental Medicine Program, University of British Columbia, Vancouver, Canada"},{"name":"Brain Research Centre and Faculty of Medicine, Division of Neurology, University of British Columbia, Vancouver, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Dahlgren","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Department of Obstetrics and Gynaecology, University of British Columbia, Vancouver, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"AD","family":"Sadovnick","sequence":"additional","affiliation":[{"name":"Brain Research Centre and Faculty of Medicine, Division of Neurology, University of British Columbia, Vancouver, Canada"},{"name":"Faculty of Medicine, Department of Medical Genetics, University of British Columbia, Vancouver, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Sayao","sequence":"additional","affiliation":[{"name":"Brain Research Centre and Faculty of Medicine, Division of Neurology, University of British Columbia, Vancouver, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Synnes","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Department of Pediatrics, University of British Columbia, Vancouver, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"Tremlett","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Experimental Medicine Program, University of British Columbia, Vancouver, Canada"},{"name":"Brain Research Centre and Faculty of Medicine, Division of Neurology, University of British Columbia, Vancouver, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2011,9,13]]},"reference":[{"key":"bibr1-1352458511422244","doi-asserted-by":"publisher","DOI":"10.1177\/1352458509106543"},{"key":"bibr2-1352458511422244","doi-asserted-by":"publisher","DOI":"10.1002\/pds.615"},{"key":"bibr3-1352458511422244","doi-asserted-by":"publisher","DOI":"10.1191\/1352458504ms1083oa"},{"key":"bibr4-1352458511422244","unstructured":"Neura.net. Pregnancy in MS: Treatment during pregnancy [online]. Available at: www.neura.net\/channels\/1.asp?id=512&prev_place=&cps=0&cpp=2 (accessed 23 August 2010)."},{"key":"bibr5-1352458511422244","doi-asserted-by":"publisher","DOI":"10.2307\/2991522"},{"key":"bibr6-1352458511422244","unstructured":"Biogen Idec. Avonex\u00ae (interferon beta-1a) [online]. Available at: www.accessdata.fda.gov\/drugsatfda_docs\/label\/2007\/103628s5115lbl.pdf (accessed 14 December 2010)."},{"key":"bibr7-1352458511422244","unstructured":"Merck Serono. Rebif\u00ae (interferon beta-1a) [online]. Available at: www.accessdata.fda.gov\/drugsatfda_docs\/label\/2005\/103780s5062lbl.pdf (accessed 14 December 2010)."},{"key":"bibr8-1352458511422244","unstructured":"Bayer HealthCare. Betaseron\u00ae (interferon beta-1b) [online]. Available at: berlex.bayerhealthcare.com\/html\/products\/pi\/Betaseron_PI.pdf (accessed 14 December 2010)."},{"key":"bibr9-1352458511422244","unstructured":"Teva Pharmaceuticals. Copaxone\u00ae (glatiramer acetate) [online]. Available at: www.copaxone.com\/pdf\/prescribinginformation.pdf (accessed 14 December 2010)."},{"key":"bibr10-1352458511422244","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3181fd62bb"},{"key":"bibr11-1352458511422244","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-008-0909-4"},{"key":"bibr12-1352458511422244","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-010-5652-y"},{"key":"bibr13-1352458511422244","unstructured":"British Columbia Perinatal Health Program. British Columbia perinatal database registry annual report 2007 [online]. Available at: www.perinatalservicesbc.ca\/sites\/bcrcp\/files\/AnnualReport\/BCPHP_2007AR.pdf (accessed 23 August 2010)."},{"key":"bibr14-1352458511422244","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.42.5.991"},{"key":"bibr15-1352458511422244","doi-asserted-by":"publisher","DOI":"10.1017\/S0317167100035782"},{"key":"bibr16-1352458511422244","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410130302"},{"key":"bibr17-1352458511422244","doi-asserted-by":"publisher","DOI":"10.1002\/ana.1032"},{"key":"bibr18-1352458511422244","doi-asserted-by":"publisher","DOI":"10.2105\/AJPH.92.8.1323"},{"key":"bibr19-1352458511422244","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-0528.2000.tb11661.x"},{"key":"bibr20-1352458511422244","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.33.11.1444"},{"key":"bibr21-1352458511422244","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-3016.11.s1.9.x"},{"key":"bibr22-1352458511422244","doi-asserted-by":"publisher","DOI":"10.1111\/j.1523-536X.1991.tb00065.x"},{"key":"bibr23-1352458511422244","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(64)80188-8"},{"key":"bibr24-1352458511422244","doi-asserted-by":"publisher","DOI":"10.1177\/1352458510372629"},{"key":"bibr25-1352458511422244","unstructured":"British Columbia Ministry of Health Services. Disease modifying drug coverage for multiple sclerosis [online]. Available at: www.health.gov.bc.ca\/exforms\/pharmacare\/5351fil.pdf (accessed 12 March 2011)."},{"key":"bibr26-1352458511422244","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000277703.74115.d2"},{"key":"bibr27-1352458511422244","doi-asserted-by":"publisher","DOI":"10.1001\/archneurol.2009.138"},{"key":"bibr28-1352458511422244","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000188898.02018.95"},{"key":"bibr29-1352458511422244","doi-asserted-by":"publisher","DOI":"10.1002\/ana.22483"},{"key":"bibr30-1352458511422244","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200102153440701"},{"key":"bibr31-1352458511422244","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000180575.77021.c4"},{"key":"bibr32-1352458511422244","doi-asserted-by":"publisher","DOI":"10.1590\/S0004-282X2009000400015"},{"key":"bibr33-1352458511422244","first-page":"969","volume":"24","author":"Fragoso YD","year":"2010","journal-title":"CNS Drugs"},{"key":"bibr34-1352458511422244","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000168905.97207.d0"},{"key":"bibr35-1352458511422244","doi-asserted-by":"publisher","DOI":"10.1177\/1352458510394610"},{"key":"bibr36-1352458511422244","doi-asserted-by":"publisher","DOI":"10.1177\/1352458509102366"},{"key":"bibr37-1352458511422244","first-page":"52","volume":"10","author":"Dwosh E","year":"2003","journal-title":"Int MS J"},{"key":"bibr38-1352458511422244","first-page":"67","volume":"10","author":"Dwosh E","year":"2003","journal-title":"Int MS J"}],"container-title":["Multiple Sclerosis Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1352458511422244","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1352458511422244","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1352458511422244","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T03:32:24Z","timestamp":1777692744000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1352458511422244"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,9,13]]},"references-count":38,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012,4]]}},"alternative-id":["10.1177\/1352458511422244"],"URL":"https:\/\/doi.org\/10.1177\/1352458511422244","relation":{},"ISSN":["1352-4585","1477-0970"],"issn-type":[{"value":"1352-4585","type":"print"},{"value":"1477-0970","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,9,13]]}}}